Josh Jennings
Stock Analyst at Morgan Stanley
(2.61)
# 2,296
Out of 5,090 analysts
14
Total ratings
54.55%
Success rate
18.14%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Josh Jennings
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DCBO Docebo | Maintains: Overweight | $49 → $53 | $21.75 | +143.68% | 5 | Nov 10, 2023 | |
| PODD Insulet | Maintains: Outperform | $350 → $300 | $316.45 | -5.20% | 3 | Aug 9, 2023 | |
| BFLY Butterfly Network | Initiates: Outperform | $20 | $3.06 | +553.59% | 1 | Jun 21, 2021 | |
| MDWD MediWound | Initiates: Outperform | $63 | $18.07 | +248.64% | 1 | Sep 28, 2017 | |
| CTSO Cytosorbents | Initiates: Outperform | $7 | $0.74 | +848.38% | 1 | Jun 7, 2017 | |
| EW Edwards Lifesciences | Maintains: Outperform | $43 → $40 | $85.78 | -53.37% | 3 | Dec 7, 2016 |
Docebo
Nov 10, 2023
Maintains: Overweight
Price Target: $49 → $53
Current: $21.75
Upside: +143.68%
Insulet
Aug 9, 2023
Maintains: Outperform
Price Target: $350 → $300
Current: $316.45
Upside: -5.20%
Butterfly Network
Jun 21, 2021
Initiates: Outperform
Price Target: $20
Current: $3.06
Upside: +553.59%
MediWound
Sep 28, 2017
Initiates: Outperform
Price Target: $63
Current: $18.07
Upside: +248.64%
Cytosorbents
Jun 7, 2017
Initiates: Outperform
Price Target: $7
Current: $0.74
Upside: +848.38%
Edwards Lifesciences
Dec 7, 2016
Maintains: Outperform
Price Target: $43 → $40
Current: $85.78
Upside: -53.37%